Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other financing activities (2022 - 2024)

Historic Other financing activities for Verrica Pharmaceuticals (VRCA) over the last 3 years, with Q3 2024 value amounting to $163000.0.

  • Verrica Pharmaceuticals' Other financing activities rose 16721.31% to $163000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $163000.0, marking a year-over-year decrease of 578.03%. This contributed to the annual value of $17000.0 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2024, Verrica Pharmaceuticals' Other financing activities is $163000.0, which was up 16721.31% from -$173000.0 recorded in Q4 2023.
  • Over the past 5 years, Verrica Pharmaceuticals' Other financing activities peaked at $163000.0 during Q3 2024, and registered a low of -$173000.0 during Q4 2023.
  • Over the past 3 years, Verrica Pharmaceuticals' median Other financing activities value was $61000.0 (recorded in 2023), while the average stood at $36000.0.
  • Within the past 5 years, the most significant YoY rise in Verrica Pharmaceuticals' Other financing activities was 16721.31% (2024), while the steepest drop was 16721.31% (2024).
  • Verrica Pharmaceuticals' Other financing activities (Quarter) stood at $17000.0 in 2022, then plummeted by 1117.65% to -$173000.0 in 2023, then skyrocketed by 194.22% to $163000.0 in 2024.
  • Its Other financing activities stands at $163000.0 for Q3 2024, versus -$173000.0 for Q4 2023 and $61000.0 for Q3 2023.